Our previous research has also confirmed that, EVs derived from tumor cells carry programmed death ligand 1 (PD-L1) on their surfaces, which can directly bind to programmed cell death protein 1 on CD8+ T cells, thereby mediating systemic immune suppression at sites distant from the primary tumor 28,29. The gene discussed is CD8A; the disease is neoplasm.